Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

Stock Information for Profound Medical Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Profound Medical Corp.

Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Profound Medical to Release First Quarter 2026 Financial Results on May 7 - Conference Call to Follow
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. Investigated by the Portnoy Law Firm
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.